What interval makes sense for repeating LDL-C on a GLP-1 receptor agonist?

Stated plainly: LDL-C · a GLP-1 receptor agonist.

I am trying to build something sustainable rather than something thorough that I will abandon.

I have already decided the broad direction; this is about the specifics.

How would you structure this, and what thresholds would you set in advance?

The short version: a small, well-chosen panel with a baseline beats a large one without.

Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.

Headline results, principal programmes

It helps to be literal here: haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.

Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.

Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.

Keep the full report, not the number. You will need the units and the interval later.

Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.

Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.

Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.

Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.

One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.

Start with a baseline. A result taken before anything started converts most later ambiguity into a simple comparison, and it cannot be obtained retrospectively.

Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.

Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.

External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.

The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.

Decide the action for each result before you order the test.

Standardise the conditions — same time of day, same fasting state, same laboratory — or you are measuring the conditions rather than yourself.

A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.

Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.

Baseline first, then a repeat under identical conditions. Everything else is secondary.

Before reacting to any single value, check whether it is outside the interval by an amount larger than the assay's own variation.

A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.

Research-use compounds are not approved for human use, and no panel makes that safer.

Same laboratory, same time, same fasting state, or the comparison is not a comparison.